Introduction
============

Angiogenesis is important in tumor progression, and has been one of the targets of cancer treatment ([@b1-ol-0-0-4246]). Angiogenesis inhibitors have been demonstrated to confer survival benefits in patients with colorectal, non-small cell lung, breast and renal cell carcinoma ([@b2-ol-0-0-4246]). Several angiogenesis inhibitors are currently available worldwide, and unique adverse events associated with their use, which do not occur with traditional chemotherapy regimens, have been suspected ([@b3-ol-0-0-4246]). These include modest-to-mild hypertension, proteinuria, and epistaxis, which are manageable, although serious adverse events such as gastrointestinal hemorrhage, gastrointestinal tract perforation, and arterial and venous thromboembolisms have also been reported ([@b2-ol-0-0-4246]).

The oral tyrosine kinase inhibitor pazopanib was the first molecular-targeted agent approved for the treatment of advanced soft tissue sarcoma ([@b4-ol-0-0-4246]). Pazopanib is a novel multi-kinase inhibitor that inhibits angiogenesis, and has been demonstrated to improve progression-free survival, compared with placebo, in the PALETTE trial ([@b4-ol-0-0-4246]). The majority of the adverse events reported for this drug, including hypertension, fatigue and diarrhea, were mild-to-modest, although severe hemorrhage has also been reported ([@b5-ol-0-0-4246]--[@b8-ol-0-0-4246]).

Thus far, bleeding events associated with the use of bevacizumab, sorafenib, sunitinib and pazopanib have been reported ([@b9-ol-0-0-4246],[@b10-ol-0-0-4246]). To avoid them, care must be taken when selecting patients for angiogenesis treatments ([@b10-ol-0-0-4246]).

In the present study, a case of mortality due to massive hemorrhage following remarkable tumor shrinkage induced by radiation therapy and subsequent pazopanib treatment is reported.

Case report
===========

A 71-year-old Japanese woman was referred to the Department of Neurosurgery of Keio University School of Medicine (Tokyo, Japan) in September 2007 for a left buccal palsy. The patient had never smoked and did not drink alcohol. Her medical history revealed hypertension, which was well-controlled with candesartan (8 mg/day), and chronic hepatitis C, which was inactive. Her performance status was evaluated as 1, due to hearing impairment. Written informed consent was obtained from the patient\'s guardian for the publication of the study.

An infratemporal fossa tumor was diagnosed and removed surgically. The pathological diagnosis was leiomyosarcoma. In total, the patient underwent six attempts of surgical removal and three courses of radiotherapy (64 Gy/32 fractions, 54 Gy/27 fractions and 60 Gy/30 fractions; Clinac® iX System Linear Accelerator; Varian Medical Systems, Palo Alto, CA, USA) for local recurrence. Metastasis to the right lung was later identified, with rapidly progressing local invasion from the left infratemporal fossa into the maxillary sinus and oral cavity. In consequence, the patient underwent four cycles of systemic chemotherapy over three months with mesna (1500 mg; intravenous), adriamycin (60 mg/m^2^; intravenous), ifosfamide (2.5 g/m^2^; intravenous) and dacarbazine (300 mg/m^2^; intravenous) (MAID) regimen. Remarkable responses were achieved in the locally advanced primary tumors and pulmonary lesions. Following 2 years of treatment, although the primary lesion had stabilized, the lung metastasis had progressed as revealed by a computed tomography scan ([Fig. 1A](#f1-ol-0-0-4246){ref-type="fig"}; Aquilion™; Toshiba Medical Systems Ltd., Otawara, Japan). A further course of MAID chemotherapy was administered. However, the tumor was refractory to this treatment, and the patient was referred to the Keio Cancer Center of Keio University School of Medicine (Tokyo, Japan) in January 2013. Since her pulmonary lesion was increasing in size, thus increasing the risk of airway obstruction, radiation therapy (50 Gy/20 fractions; Clinac® iX System Linear Accelerator) was administered to the patient, which resulted in 13% tumor shrinkage ([Fig. 1B](#f1-ol-0-0-4246){ref-type="fig"}). Subsequently, the patient was administered oral pazopanib daily (800 mg/day; GlaxoSmithKline, Brentford, UK) as palliative chemotherapy in the outpatient clinic.

Upon initiation of pazopanib, grade 2 hypertension and grade 2 mucositis \[according to the National Cancer Institute Common Terminology Criteria for Adverse Events ([@b11-ol-0-0-4246])\] were observed on day 14. Due to the development of corns on both feet on day 55 (known as grade 3 palmar-plantar erythrodysesthesia syndrome), pazopanib was ceased for 2 weeks, and recommenced when this symptom had resolved. At this stage, 38% shrinkage of the tumor in the right lung was evident ([Fig. 1C](#f1-ol-0-0-4246){ref-type="fig"}). However, following 3 months of treatment, the patient suddenly vomited blood at home and succumbed to the hemorrhage.

At autopsy, the primary leiomyosarcoma in the brain and the metastasis in the right lung were confirmed. However, no ulcer formation in the gastrointestinal tract, ruptured blood vessel or cavity formation were observed.

Discussion
==========

The present study reports a case of hemorrhage-associated mortality and tumor shrinkage induced by radiation therapy, followed by pazopanib treatment. There are three main possible explanations for the fatal hemorrhage.

First, the possibility that the hemorrhage was an adverse reaction to pazopanib must be considered, since vascular endothelial growth factor (VEGF) and multi-kinase inhibitors may cause hemorrhage, and pazopanib has been reported to cause gastrointestinal and intracranial hemorrhage ([@b5-ol-0-0-4246]--[@b8-ol-0-0-4246]).

Second, the effects of radiation continue for few months post-treatment and include severe fibrosis ([@b3-ol-0-0-4246]). A previous study reported one patient who succumbed to hemorrhage upon receiving \>50 Gy of radiation to the pulmonary artery and bronchus ([@b12-ol-0-0-4246]). Furthermore, another report warned against using stereotactic body radiation therapy in patients with tumors located near the central airways due to various adverse effects, including hemorrhagic mortality ([@b13-ol-0-0-4246]). In the present case, although the patient was exposed to \<50 Gy dose, the radiation may still have been responsible for the hemorrhage.

Third, there is a risk of severe bleeding in patients with remarkable shrinkage of tumor following irradiation, which is generally associated with fibrosis in the surrounding tissues ([@b3-ol-0-0-4246]). As reported by Hui *et al* ([@b3-ol-0-0-4246]), tumor necrosis and cavitation are associated with bleeding events. Thus, tumor shrinkage following treatment with anti-angiogenic therapy is associated with an increased risk of bleeding ([@b3-ol-0-0-4246]). In the present case, although there was no cavity formation, remarkable tumor shrinkage had occurred. Considering that the lung metastasis in the present patient was adjacent to the trachea, shrinkage of the tumor may have caused perforation of the trachea and subsequent hemorrhage from the tumor.

Therefore, it may be hypothesized that the synergic effects of pazopanib, radiotherapy and tumor shrinkage may have been responsible for the bleeding in the present case.

In conclusion, remarkable tumor response associated with radiation therapy may be a risk factor for severe hemorrhage when combined with pazopanib. Thus, clinicians should be alert to the possibility of this adverse event. In this situation, delaying the introduction of pazopanib therapy may be an option. Further investigation of the possible mechanisms leading to fatal hemorrhage, and analysis of the risk factors associated with the hemorrhagic adverse events caused by VEGF and multi-kinase inhibitors, are required.

![(A) Lung metastasis pre-radiation. CT scan image revealed an 85-mm metastatic lesion in the right lung. (B) Lung metastasis post-radiation. CT scan image demonstrated a 13% reduction in size of the metastatic lesion in the right lung following radiation treatment with 50 Gy/20 fractions. (C) Lung metastasis post-pazopanib treatment. CT scan image revealed a 38% reduction in size of the metastatic lesion in the right lung following radiation and subsequent pazopanib treatment. CT, computed tomography.](ol-11-04-2408-g00){#f1-ol-0-0-4246}
